Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vamousse is a **pesticide-free, topical lice treatment** in the form of an aerosol foam or mousse, indicated for the **elimination of head lice and their eggs (nits)** in adults and children aged 2 years and older[1][2][5][7]. The **active ingredient is natrum muriaticum (sodium chloride)**, which works by **disrupting the protective lipid layer of the lice exoskeleton**, leading to dehydration and death of both adult lice and eggs, rather than utilizing neurotoxic pesticides[2][5][6][7][9][10]. The product shows efficacy against both regular and “super” lice, including pesticide-resistant strains[2][7]. Treatment involves saturating dry hair and scalp, leaving for 15 minutes, then combing to remove dead lice and nits. Effectiveness is achieved with a single application, but re-treatment is allowed if needed. Developed and marketed mainly by Alliance Pharma, Vamousse is sold as an over-the-counter OTC drug. The product is labeled as unapproved homeopathic in some jurisdictions[1]. Key inactive ingredients include isopropyl myristate, isopropyl alcohol, cocamidopropyl betaine, benzyl alcohol, ammonium benzoate, sodium lauryl sulfate, butyl lactate, vanillin, geraniol, and water[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vamousse.